Pharmacological approaches to Parkinson's disease in the different phases of evolution.
The pharmacological approaches to Parkinson's disease in the different phases of evolution (initial or slight, complete and complicated) are discussed. The modality of confronting the therapeutic approach according to the different evolutive phases makes it possible to personalize the therapy, in an attempt to obtain the optimal clinical effect with minimum side effects. Various drugs available and future perspectives are considered.
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects; D012642:Selegiline / Q000627:therapeutic use
D000929:Antidepressive Agents, Tricyclic; D000978:Antiparkinson Agents; D010276:Parasympatholytics; D011954:Receptors, Dopamine; D012642:Selegiline; D007980:Levodopa; D002262:Carboxy-Lyases